Following discussions with the company, the evaluation of concizumab has been split into 2 indications. Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors will continue as ID5099. Concizumab for treating haemophilia A or B in people 12 years and over with inhibitors will progress under a new ID number, ID6665.